Assess the data and tweets to estimate whether the closing price of $bmy will escalate or deflate at 2017-06-06. Respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-05-22,-0.1,0.4,-0.4,0.1,0.1,0.1,1.0,1.4,1.5,0.9,0.4
2017-05-23,-0.1,0.4,-0.1,0.2,0.2,-0.2,0.6,1.0,1.3,0.8,0.3
2017-05-24,1.2,1.2,-0.7,-0.7,-0.7,0.3,1.1,1.5,2.1,1.6,1.1
2017-05-25,-0.9,0.3,-1.3,1.1,1.1,-0.5,-0.1,0.4,0.9,0.6,0.1
2017-05-26,0.7,1.6,-0.1,-0.8,-0.8,0.2,0.5,1.0,1.5,1.4,0.9
2017-05-30,0.0,0.6,-0.3,-0.1,-0.1,0.2,0.3,1.0,1.3,1.5,1.1
2017-05-31,0.4,0.7,-0.2,0.0,0.0,0.1,0.2,0.8,1.1,1.5,1.1
2017-06-01,-1.0,0.0,-1.2,1.1,1.1,-0.7,-0.8,-0.4,-0.0,0.5,0.1
2017-06-02,-0.5,0.4,-0.8,0.8,0.8,-1.3,-1.4,-1.2,-0.8,-0.4,-0.6
2017-06-05,2.7,3.8,-0.3,-4.7,-4.7,3.0,3.2,3.4,3.8,4.3,4.3

2017-05-22: rt AT_USER this could be in the top 50 disruptive technologies this year.  #dcvax $nwbo $juno $kite $blue $agio $celg $gild $bmy $nvs¡­|$bmy is in three inside up winning 63.64% in the past. |valeant 
2017-05-23: rt AT_USER AT_USER watch what happens after p3 topline $nwbo buyout $cpxx style $bmy $mrk both collaborated with $nwbo $amgn¡­|somewhat positive press coverage very likely to affect bristol-myers squi
2017-05-24: rt AT_USER dcvax-l the next disruptive technology.  it will play well with others also.  $nwbo $bmy $mrk $kite $juno $exel $nvs $gild¡­|rt AT_USER dcvax-l the next disruptive technology.  it will play
2017-05-25: rt AT_USER #dcvax-l 4 #gbm #dcvaxdirect 13 cancer indications.  robust pipeline. #google $nwbo #disrupt #cancer $kite $juno $bmy $mrk¡­|fda drug approvals rebound from last year, up... $lly $bmy $pfe 
2017-05-26: AT_USER tic toc $nwbo collaborated with $bmy and $mrk because of this trial which reads out in a few weeks | members have an advantage. see track record  $bmy $pot $apa $cnq $ccl $ba| members have an 
2017-05-27: bristol-myers to hold investor teleconference on june 4 to review asco data  $bmy
2017-05-28: glycomimetics: a new angle on tackling chemo resistance  $bmy $cala $jazz $pfe $glyc got this one right, check date.|rt AT_USER introducing dcvax! $pbyi $fgen $icpt $bmy $mrk $kite $juno all good. but
2017-05-29: bristol-myers squibb co $bmy receives $61.81 average price target from analysts |bristol-myers squibb co $bmy receives $61.81 average price target from analysts |bristol-myers squibb co $bmy receives 
2017-05-30: rt AT_USER top 50 disruptive tech!  1 cell coommands hundreds.  big $. $bmy $mrk $nvs $kite $juno $icpt $blue $celg $gild #cancer no e¡­|AT_USER well said roy the real question should be why did $bmy 
2017-05-31: 3 things in biotech you should learn today: may 31, 2017  $adxs $arry $bmy $invvy|commented on glycomimetics: a new angle on tackling chemo resistance  $bmy $cala $jazz $pfe $glyc|rt AT_USER $bmy and 
2017-06-01: rt AT_USER ubs:" immuno-oncology  drugs by target : $mrk $bmy $celg $incy $iph.pa $pfe $amgn $ziop $sgne $ino $clsn ..." |rt AT_USER peruvian lawmakers seek a compulsory license for a bristol-myers hi
2017-06-02: AT_USER keytruda is kicking opdivos ass.  if $bmy  was smart they buy them n do a combo pill.  like $nvs or mrk did|is now a good time to buy $jpm $snap $bac $ibm $mpc  $teva $bmy $abbv $hot $v $mdt $
2017-06-03: amgen's imlygic shows treatment effect in metastatic melanoma patients in mid-stage study  $amgn $bmy #sitifatimah ¡­|amgen's imlygic shows treatment effect in metastatic melanoma patients in mid-stag
2017-06-04: cowen pd-1/pd-l1 market opportunity to exceed $32b in 2022 $mrk $bmy $rog $azn |rt AT_USER keynote-059 keytruda monotherapy arm in &gt;3l gastric cancer, via c fuchs $mrk $bmy #asco17 |rt AT_USER we'r
2017-06-05: bristol-myers squibb's opdivo, yervoy put the brakes on mesothelioma in phase 2  $bmy #asco17|tuesday: $tho, $acor, $rh, $tsla, $panw, $vmw, $bmy|rt AT_USER on the fly: top stock stories at midday $aa
Answer:
Assess the data and tweets to estimate whether the closing price of $bmy will escalate or deflate at 2017-06-06. Respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-05-22,-0.1,0.4,-0.4,0.1,0.1,0.1,1.0,1.4,1.5,0.9,0.4
2017-05-23,-0.1,0.4,-0.1,0.2,0.2,-0.2,0.6,1.0,1.3,0.8,0.3
2017-05-24,1.2,1.2,-0.7,-0.7,-0.7,0.3,1.1,1.5,2.1,1.6,1.1
2017-05-25,-0.9,0.3,-1.3,1.1,1.1,-0.5,-0.1,0.4,0.9,0.6,0.1
2017-05-26,0.7,1.6,-0.1,-0.8,-0.8,0.2,0.5,1.0,1.5,1.4,0.9
2017-05-30,0.0,0.6,-0.3,-0.1,-0.1,0.2,0.3,1.0,1.3,1.5,1.1
2017-05-31,0.4,0.7,-0.2,0.0,0.0,0.1,0.2,0.8,1.1,1.5,1.1
2017-06-01,-1.0,0.0,-1.2,1.1,1.1,-0.7,-0.8,-0.4,-0.0,0.5,0.1
2017-06-02,-0.5,0.4,-0.8,0.8,0.8,-1.3,-1.4,-1.2,-0.8,-0.4,-0.6
2017-06-05,2.7,3.8,-0.3,-4.7,-4.7,3.0,3.2,3.4,3.8,4.3,4.3

2017-05-22: rt AT_USER this could be in the top 50 disruptive technologies this year.  #dcvax $nwbo $juno $kite $blue $agio $celg $gild $bmy $nvs¡­|$bmy is in three inside up winning 63.64% in the past. |valeant 
2017-05-23: rt AT_USER AT_USER watch what happens after p3 topline $nwbo buyout $cpxx style $bmy $mrk both collaborated with $nwbo $amgn¡­|somewhat positive press coverage very likely to affect bristol-myers squi
2017-05-24: rt AT_USER dcvax-l the next disruptive technology.  it will play well with others also.  $nwbo $bmy $mrk $kite $juno $exel $nvs $gild¡­|rt AT_USER dcvax-l the next disruptive technology.  it will play
2017-05-25: rt AT_USER #dcvax-l 4 #gbm #dcvaxdirect 13 cancer indications.  robust pipeline. #google $nwbo #disrupt #cancer $kite $juno $bmy $mrk¡­|fda drug approvals rebound from last year, up... $lly $bmy $pfe 
2017-05-26: AT_USER tic toc $nwbo collaborated with $bmy and $mrk because of this trial which reads out in a few weeks | members have an advantage. see track record  $bmy $pot $apa $cnq $ccl $ba| members have an 
2017-05-27: bristol-myers to hold investor teleconference on june 4 to review asco data  $bmy
2017-05-28: glycomimetics: a new angle on tackling chemo resistance  $bmy $cala $jazz $pfe $glyc got this one right, check date.|rt AT_USER introducing dcvax! $pbyi $fgen $icpt $bmy $mrk $kite $juno all good. but
2017-05-29: bristol-myers squibb co $bmy receives $61.81 average price target from analysts |bristol-myers squibb co $bmy receives $61.81 average price target from analysts |bristol-myers squibb co $bmy receives 
2017-05-30: rt AT_USER top 50 disruptive tech!  1 cell coommands hundreds.  big $. $bmy $mrk $nvs $kite $juno $icpt $blue $celg $gild #cancer no e¡­|AT_USER well said roy the real question should be why did $bmy 
2017-05-31: 3 things in biotech you should learn today: may 31, 2017  $adxs $arry $bmy $invvy|commented on glycomimetics: a new angle on tackling chemo resistance  $bmy $cala $jazz $pfe $glyc|rt AT_USER $bmy and 
2017-06-01: rt AT_USER ubs:" immuno-oncology  drugs by target : $mrk $bmy $celg $incy $iph.pa $pfe $amgn $ziop $sgne $ino $clsn ..." |rt AT_USER peruvian lawmakers seek a compulsory license for a bristol-myers hi
2017-06-02: AT_USER keytruda is kicking opdivos ass.  if $bmy  was smart they buy them n do a combo pill.  like $nvs or mrk did|is now a good time to buy $jpm $snap $bac $ibm $mpc  $teva $bmy $abbv $hot $v $mdt $
2017-06-03: amgen's imlygic shows treatment effect in metastatic melanoma patients in mid-stage study  $amgn $bmy #sitifatimah ¡­|amgen's imlygic shows treatment effect in metastatic melanoma patients in mid-stag
2017-06-04: cowen pd-1/pd-l1 market opportunity to exceed $32b in 2022 $mrk $bmy $rog $azn |rt AT_USER keynote-059 keytruda monotherapy arm in &gt;3l gastric cancer, via c fuchs $mrk $bmy #asco17 |rt AT_USER we'r
2017-06-05: bristol-myers squibb's opdivo, yervoy put the brakes on mesothelioma in phase 2  $bmy #asco17|tuesday: $tho, $acor, $rh, $tsla, $panw, $vmw, $bmy|rt AT_USER on the fly: top stock stories at midday $aa
Answer:+Fall